Genetic Association between Matrix Metalloproteinases Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis

Studies suggests that ( ) -1306 C/T and -1607 1G/2G polymorphisms affect the risk of prostate cancer. However, the conclusions remain controversial and no pooled evidence of this topic has been published. Therefore, we aimed to perform a meta-analysis to shed some light on the controversial conclusi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in physiology 2017-12, Vol.8, p.975-975
Main Authors: Weng, Hong, Zeng, Xian-Tao, Wang, Xing-Huan, Liu, Tong-Zu, He, Da-Lin
Format: Article
Language:English
Subjects:
genetic variation
matrix metalloproteinases
meta-analysis
Physiology
polymorphism
prostate cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies suggests that ( ) -1306 C/T and -1607 1G/2G polymorphisms affect the risk of prostate cancer. However, the conclusions remain controversial and no pooled evidence of this topic has been published. Therefore, we aimed to perform a meta-analysis to shed some light on the controversial conclusion pertaining to the associations of -1306 C/T and -1607 1G/2G polymorphisms with prostate cancer susceptibility. A thorough literature search was performed up to August, 2016 with the PubMed, EMBASE, CBM, CNKI, and Wanfang databases. Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to address the correlations between these polymorphisms and risk of prostate cancer. The meta-analysis included six studies (1,921 patients and 1,988 controls) on -1306 C/T polymorphism and three studies on -1607 1G/2G polymorphism (438 patients and 394 controls), respectively. The overall results of meta-analysis showed that an elevated risk of the disease was implicated in -1306 C/T polymorphism under two genetic models (CT vs. CC: OR = 1.78, 95% CI = 1.33-2.38; TT+CT vs. CC: OR = 1.62, 95% CI = 1.24-2.12) and no significant association was observed between -1607 1G/2G polymorphism and the risk of prostate cancer. The subgroup analysis results of -1306 C/T polymorphism were similar to the overall results. However, decreased risk of prostate cancer was observed in the Caucasians for -1607 1G/2G polymorphism. Current meta-analysis indicates that -1306 C/T polymorphism is associated with elevated risk of prostate cancer, but -1607 1G/2G polymorphism may inhibit the occurrence of prostate cancer in Caucasians. Further studies are warranted to verify the conclusions.
ISSN:1664-042X
1664-042X
DOI:10.3389/fphys.2017.00975